Treatment of neurofibromatosis 1-associated malignant peripheral nerve sheath tumors: a systematic review

  • Muhibullah S. ToraEmail author
  • Dimitrios Xenos
  • Pavlos Texakalidis
  • Nicholas M. Boulis


Malignant peripheral nerve sheath tumors (MPNST) are a rare and aggressive group of tumors that are challenging to treat. Neurofibromatosis type 1 (NF-1)-associated MPNSTs have been associated with poorer clinical outcomes. The treatment options for NF-1-associated MPNSTs broadly include surgery (SG), chemotherapy (CT), and adjuvant radiotherapy (RT). Overall, the role and efficacy of CT and RT are unclear. Examination of existing literature for studies reporting on NF-1-associated MPNSTs and respective treatment-related outcomes was conducted. We conducted a systematic review according to PRISMA guidelines in PubMed/Medline and Cochrane databases of studies which reported treatment-specific outcomes in NF-1-associated MPNSTs. The literature search found 444 records after removal of duplicates. The present study included 50 patients across 12 observational studies. All of the included studies reported data on overall survival (OS 52%, n = 26/50) but mean follow-up in months among the studies and among patients varied widely, between 10.85 (SD, ± 10.38) and 192 (SD, ± 98.22). From the included studies, patients underwent either SG alone (n = 21), SG + CT (n = 10), SG + RT (n = 7), or SG + CT + RT (n = 12). The quality of evidence in the literature regarding optimal treatment options for NF-1-associated MPNSTs remains tenuous. Future retrospective and prospective comparative trials should consider adherence to a set of reporting guidelines to improve the quality of evidence in the literature with respect to individual treatment-related outcomes. The need for prospective multi-institutional efforts cannot be overstated.


Malignant peripheral nerve sheath tumor MPNST Neurofibromatosis 1 NF-1 Publishing guidelines Chemotherapy Radiotherapy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable for this systematic review.

Informed consent

Not applicable for this systematic review.

Supplementary material

10143_2019_1135_MOESM1_ESM.docx (15 kb)
Supplemental Table 1 (DOC× 15 kb)


  1. 1.
    Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, Maki RG (2014) Malignant peripheral nerve sheath tumors. Oncologist 19(2):193–201CrossRefGoogle Scholar
  2. 2.
    Watson KL, Al Sannaa GA, Kivlin CM et al (2017) Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg 126(1):319–329CrossRefGoogle Scholar
  3. 3.
    Vasconcelos RAT, Coscarelli PG, Alvarenga RP, Acioly MA (2017) Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. Arq Neuropsiquiatr 75(6):366–371CrossRefGoogle Scholar
  4. 4.
    Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA (2013) Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology 15(2):135–147CrossRefGoogle Scholar
  5. 5.
    Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D (2009) Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249(6):1014–1022CrossRefGoogle Scholar
  6. 6.
    LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM, Brennan MF, Singer S (2013) Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol 20(1):66–72CrossRefGoogle Scholar
  7. 7.
    Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107(5):1065–1074CrossRefGoogle Scholar
  8. 8.
    Feng CJ, Ma H, Liao WC (2015) Superficial or cutaneous malignant peripheral nerve sheath tumor--clinical experience at Taipei Veterans General Hospital. Ann Plast Surg 74(Suppl 2):S85–S88CrossRefGoogle Scholar
  9. 9.
    Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62(5):1573–1577Google Scholar
  10. 10.
    Higham CS, Steinberg SM, Dombi E et al (2017) SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma 2017:8685638CrossRefGoogle Scholar
  11. 11.
    Shurell-Linehan E, DiPardo BJ, Elliott IA et al (2019) Pathologic response to neoadjuvant therapy is associated with improved long-term survival in high-risk primary localized malignant peripheral nerve sheath tumors. Am J Clin Oncol 42:426–431CrossRefGoogle Scholar
  12. 12.
    Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, Fatyga A, Budka A, Balwierz W, Sobol G, Zalewska-Szewczyk B, Rychlowska-Pruszynska M, Klepacka T, Dembowska-Baginska B, Kazanowska B, Gabrych A, Bien E (2018) Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol 144(3):519–529CrossRefGoogle Scholar
  13. 13.
    Bradford D, Kim A (2015) Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options in Oncol 16(3):328CrossRefGoogle Scholar
  14. 14.
    Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefGoogle Scholar
  15. 15.
    An HY, Hong KT, Kang HJ, Choi JY, Hong CR, Kim HY, Choi TH, Kang CH, Kim HS, Cheon JE, Park SH, Park JD, Park KD, Shin HY (2017) Malignant peripheral nerve sheath tumor in children: a single-institute retrospective analysis. Pediatr Hematol Oncol 34(8):468–477CrossRefGoogle Scholar
  16. 16.
    Alina B, Sebastian JA, Gerardo C (2015) Malignant triton tumors in sisters with clinical neurofibromatosis type 1. Case Rep Oncol Med 2015:405351Google Scholar
  17. 17.
    Schaefer IM, Fletcher CD (2015) Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: clinicopathologic characterization in a series of 9 cases. Am J Surg Pathol 39(9):1234–1241CrossRefGoogle Scholar
  18. 18.
    Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM (2011) Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 34(4):417–421CrossRefGoogle Scholar
  19. 19.
    del Carmen Baena-Ocampo L, Reyes-Sanchez A, Alpizar-Aguirre A, Rosales-Olivares LM (2009) Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: report of two clinical cases. Cir Cir 77(5):391–395Google Scholar
  20. 20.
    Rekhi B, Jambhekar NA, Puri A, Agrawal M, Chinoy RF (2008) Clinicomorphologic features of a series of 10 cases of malignant triton tumors diagnosed over 10 years at a tertiary cancer hospital in Mumbai, India. Ann Diagn Pathol 12(2):90–97CrossRefGoogle Scholar
  21. 21.
    Kim JG, Sung WJ, Kim DH, Kim YH, Sohn SK, Lee KB (2005) Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass. Korean J Intern Med 20(1):100–104CrossRefGoogle Scholar
  22. 22.
    Coffin CM, Cassity J, Viskochil D, Randall RL, Albritton K (2004) Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A 127A(1):40–43CrossRefGoogle Scholar
  23. 23.
    Asavamongkolkul A, Jiranantakan T, Waikakul S, Phompitaksa K, Muangsomboon S (2001) Malignant peripheral nerve sheath tumor with neurofibromatosis type 1: a 2-case report and review of the literature. J Med Assoc Thail 84(2):285–293Google Scholar
  24. 24.
    Chang SM, Ho WL (1994) Malignant peripheral nerve sheath tumor: a study of 21 cases. Zhonghua Yi Xue Za Zhi (Taipei) 54(2):122–130Google Scholar
  25. 25.
    Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM (1984) Malignant peripheral nerve sheath tumors in childhood. J Neuro-Oncol 2(3):241–248CrossRefGoogle Scholar
  26. 26.
    Ogose A, Hotta T, Uchiyama S, Matsumoto Y, Hasegawa K, Takahashi HE (2001) Retroperitoneal malignant peripheral nerve sheath tumor associated with scoliosis in neurofibromatosis. J Spinal Disord 14(3):260–263CrossRefGoogle Scholar
  27. 27.
    Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC (2017) Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma 2017:7429697CrossRefGoogle Scholar
  28. 28.
    Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27(19):3133–3140CrossRefGoogle Scholar
  29. 29.
    Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH (2009) Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 27(19):3148–3153CrossRefGoogle Scholar
  30. 30.
    Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH (2016) SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6):868–874CrossRefGoogle Scholar
  31. 31.
    Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, de Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23(33):8422–8430CrossRefGoogle Scholar
  32. 32.
    Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1):197–203CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, School of MedicineEmory University HospitalAtlantaUSA
  2. 2.Department of Biomedical EngineeringGeorgia Institute of TechnologyAtlantaUSA
  3. 3.Medical SchoolAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations